Literature DB >> 3009386

Atriopeptin II relaxes and elevates cGMP in bovine pulmonary artery but not vein.

L J Ignarro, K S Wood, R G Harbison, P J Kadowitz.   

Abstract

Atriopeptin II, a 23-amino acid synthetic peptide fragment of atrial natriuretic factor, caused an endothelium-independent relaxation of isolated precontracted rings of bovine intrapulmonary artery that was accompanied by the concomitant accumulation of guanosine 3',5'-cyclic monophosphate (cGMP) but not adenosine 3',5'-cyclic monophosphate. In contrast, rings of intrapulmonary vein were unaffected by atriopeptin II whether or not endothelium was present. Whereas methylene blue, an inhibitor of soluble guanylate cyclase, abolishes endothelium-dependent and independent arterial relaxation and cGMP accumulation in response to acetylcholine and glyceryl trinitrate, respectively, methylene blue failed to alter these responses to atriopeptin II. Similarly, the effects of atriopeptin II were unaltered by propranolol, indomethacin, or atropine. These results indicate that relaxation elicited by atriopeptin II may be selective for arterial smooth muscle receptors, does not require endothelial cells, and does not involve the soluble form of guanylate cyclase, although cGMP accumulation is stimulated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009386     DOI: 10.1152/jappl.1986.60.4.1128

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

1.  Atrial natriuretic peptide.

Authors:  N Modi; J P Midgley
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts.

Authors:  D B McNamara; J T Light; R K Minkes; R M Saroyan; P Kvamme; N Rowe; W R Webb; L Fox; M D Kerstein; N L Mills
Journal:  Mol Cell Biochem       Date:  1992-11-04       Impact factor: 3.396

3.  Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.

Authors:  H Jin; R H Yang; Y F Chen; R M Jackson; S Oparil
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  Hemodynamic and humoral effects of atrial natriuretic peptide on pulmonary circulation after cardiac surgery.

Authors:  Keisuke Morimoto; Iwao Taniguchi; Shigeto Miyasaka; Shingo Ishiguro; Shigetsugu Ohgi
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

5.  A comparison of the vasodilator responses to atrial peptides in the pulmonary and renal arteries of the pig in vitro.

Authors:  T L Jansen; A H Morice; M J Brown
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

6.  Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

Authors:  S Adnot; P Andrivet; P E Chabrier; J Piquet; P Plas; P Braquet; F Roudot-Thoraval; C Brun-Buisson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

7.  Raised circulating plasma levels of atrial natriuretic peptide in adolescent and adult patients with cystic fibrosis and pulmonary artery hypertension.

Authors:  O C Burghuber; E Hartter; M Weissel; W Wolosczcuk; M Götz
Journal:  Lung       Date:  1991       Impact factor: 2.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.